OBJECTIVE: To evaluate the response to recombinant GH treatment and adverse events in children with Prader-Willi syndrome (PWS) from KIGS, the Pfizer International Growth Database. PATIENTS: A total of 328 children (274 prepubertal, median age 6.0 years;
Growth hormone treatment and adverse events in Prader-Willi syndrome: Data from KIGS (the Pfizer International Growth Database).All Scholarly Works
Document TypeArticle, Peer-reviewed
Citation InformationClin Endocrinol (Oxf). 2006 Aug;65(2):178-85.